Podium to Practice: EHA 2026 – Lymphoma: FRONTMIND in Frontline DLBCL
OR
Studies / Trials Discussed
S101 – TAFASITAMAB PLUS LENALIDOMIDE AND R-CHOP FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS FROM THE PHASE 3 FRONTMIND STUDY
Co-Chairs
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
This program has been made possible through unrestricted support from Merck.
Studies/trials discussed:
S101 – TAFASITAMAB PLUS LENALIDOMIDE AND R-CHOP FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS FROM THE PHASE 3 FRONTMIND STUDY
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.